Matrix Capital Management

Total investments

40

Average round size

125M

Portfolio companies

27

Rounds per year

1.60

Lead investments

8

Follow on index

0.33

Exits

3

Areas of investment
BiotechnologySoftwareFinTechArtificial IntelligenceMachine LearningHealth CareLife SciencePharmaceuticalTherapeuticsBiopharma

Summary

Matrix Capital Management is the famous VC, which was founded in 1999. The main office of represented VC is situated in the Waltham. The company was established in North America in United States.

This organization was formed by David Goel, Paul Ferri. Besides them, we counted 7 critical employees of this fund in our database.

The standard case for the fund is to invest in rounds with 4-5 partakers. Despite the Matrix Capital Management, startups are often financed by Valar Ventures, Viking Global Investors, Illumina Accelerator. The meaningful sponsors for the fund in investment in the same round are Matrix Partners, Valar Ventures, Worldview Technology Partners. In the next rounds fund is usually obtained by Valar Ventures, TechAccel LLC, TCV.

Among the most popular fund investment industries, there are SaaS, Artificial Intelligence. The fund has no specific favorite in a number of founders of portfolio startups. If startup sums 4 of the founder, the chance for it to be financed is low. Among the most popular portfolio startups of the fund, we may highlight Adaptive Biotechnologies, Encoded Therapeutics, Inc., EpiBiome. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Moreover, a startup needs to be at the age of 4-5 years to get the investment from the fund.

Opposing the other organizations, this Matrix Capital Management works on 18 percentage points less the average amount of lead investments. Deals in the range of 50 - 100 millions dollars are the general things for fund. When the investment is from Matrix Capital Management the average startup value is 500 millions - 1 billion dollars. The high activity for fund was in 2016. The top amount of exits for fund were in 2019. Considering the real fund results, this VC is 2 percentage points more often commits exit comparing to other organizations. The fund is constantly included in less than 2 deals per year.

Show more

Investor highlights

Stage focus
Seed

Discover reliable insights

Find relevant VC investors, identify key contacts and secure funding opportunities.

Investments analytics

Analytics

Total investments
40
Lead investments
8
Exits
3
Rounds per year
1.60
Follow on index
0.33
Investments by industry
  • Biotechnology (24)
  • Health Care (24)
  • Pharmaceutical (9)
  • Biopharma (9)
  • Artificial Intelligence (7)
  • Show 36 more
Investments by region
  • United States (34)
  • New Zealand (3)
Peak activity year
2021
Number of Unicorns
2
Number of Decacorns
2
Number of Minotaurs
1

Discover reliable insights

Leverage validated data, identify key contacts and secure funding opportunities for your business.

Quantitative data

Avg. startup age at the time of investment
7
Avg. valuation at time of investment
262M
Group Appearance index
0.95
Avg. company exit year
5
Avg. multiplicator
1.97
Strategy success index
0.70

Need more data?

Get access to full data about investors, including their team, contact information, and historic data.

Latest deals

Company name Deal date Industry Deal stage Deal size Location
ReCode Therapeutics 29 Jun 2022 Biotechnology, Health Care, Wellness, Pharmaceutical, Biopharma Early Stage Venture 120M United States, Texas, Dallas
Rivos 16 Apr 2024 Early Stage Venture 250M United States, California, Mountain View
How we get our data

At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).

Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.